APP and liver cancer: The results showed that the expressions of the aforementioned targets were downregulated in CR-SR, CR, and SR, which suggested that CR-SR, CR, and SR can exert an anti-liver cancer effect through the inhibition of SRC, SRC, EGFR, ESR1, PTGS2, and APP.